ArticleTransfusion2026
A case report of soluble A antigen confounding the blood type in a haplo-identical hematopoietic stem cell transplant patient with graft-versus-host disease.
Article in Transfusion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundABO-incompatible (ABOi) hematopoietic stem cell transplantation (HSCT) is often associated with ABO discrepancies post-HSCT. Re-emergence of the patient's original type post-HSCT may signal graft loss, disease relapse, recent transfusion, or soluble ABO antigen. We present a group A pediatric patient with leukemia who underwent a minor ABOi HSCT from a group O donor with persistent and increasing A reactivity 2 years post-HSCT.
methodsThe patient's electronic medical and laboratory records were reviewed. ABO, Lewis typing, and direct antiglobulin (DAT) tests were performed by column agglutination and/or tube method. Soluble anti-A was demonstrated by adsorption and human anti-A neutralization. Elution of soluble A antigen was performed by incubation of patient red cells with group A
resultsThe patient typed as Le(a-b+) and demonstrated 1+ reactivity with anti-A reagent, which increased (4+) during an episode of gastrointestinal graft-versus-host disease (GVHD). There was no evidence of disease relapse with 100% donor cells by molecular testing, normal blood counts, and a negative DAT. A high level of soluble A-antigen in patient plasma was demonstrated by adsorption and anti-A neutralization studies. Finally, soluble A antigen was successfully eluted from patient RBCs to reveal only group O donor type RBCs. DISCUSSION: We present a case of persistent A antigen post-ABOi HSCT due to soluble A antigen of patient origin. Soluble A antigen was demonstrated using adsorption, neutralization studies, and a modified elution method previously described for Lewis antigens. This case suggests increased soluble ABO antigen in the setting of gut GVHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.